1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Nephros, Inc.
  6. News
  7. Summary
    NEPH   US6406714005

NEPHROS, INC.

(NEPH)
  Report
Delayed Nasdaq  -  03:59 2022-08-17 pm EDT
1.460 USD   -12.57%
08/15NEPHROS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/10NEPHROS : Announces Results for Quarter Ended June 30, 2022 - Form 8-K
PU
08/10TRANSCRIPT : Nephros, Inc., Q2 2022 Earnings Call, Aug 10, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nephros First Quarter 2022 Financial Results Conference Call

04/27/2022 | 07:31am EDT

SOUTH ORANGE, NJ, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that it will file its first-quarter financial results on Wednesday, May 4, 2022 after market close and will host a conference call that same day at 4:30 PM ET.

Participants may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285

Upon joining, please ask to be joined into the Nephros conference call.

A replay of the call can be accessed until May 11th, 2022 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access code: 3792199. 

An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

About Nephros

Nephros, Inc. is a company committed to improving the human relationship with water through leading, accessible technology. We provide innovative filtration and pathogen detection as part of an integrated approach to water safety that combines science, solutions, and support services. Nephros products serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency responses for water management. For more information about Nephros, please visit us at nephros.com.

Investor RelationsContacts:

Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com

Andy Astor, CEO
Nephros, Inc.
(201) 345-0824
andy@nephros.com


Primary Logo


© GlobeNewswire 2022
All news about NEPHROS, INC.
08/15NEPHROS INC Management's Discussion and Analysis of Financial Condition and Results of..
AQ
08/10NEPHROS : Announces Results for Quarter Ended June 30, 2022 - Form 8-K
PU
08/10TRANSCRIPT : Nephros, Inc., Q2 2022 Earnings Call, Aug 10, 2022
CI
08/10Earnings Flash (NEPH) NEPHROS Reports Q2 Revenue $2.9M, vs. Street Est of $2.9M
MT
08/10Nephros, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2022
CI
08/10Nephros Announces Results for Quarter Ended June 30, 2022
AQ
07/27Nephros Second Quarter 2022 Financial Results Conference Call
AQ
07/06NEPHROS : Announces Preliminary Results for Quarter Ended June 30, 2022 and Projects Posit..
PU
07/06Nephros, Inc. Provides Earning Guidance for the Second Quarter Ended June 30, 2022
CI
07/06Nephros Announces Preliminary Results for Quarter Ended June 30, 2022 and Projects Posi..
AQ
More news
Analyst Recommendations on NEPHROS, INC.
More recommendations
Financials (USD)
Sales 2022 11,0 M - -
Net income 2022 -5,12 M - -
Net cash 2022 3,37 M - -
P/E ratio 2022 -2,94x
Yield 2022 -
Capitalization 15,1 M 15,1 M -
EV / Sales 2022 1,07x
EV / Sales 2023 0,86x
Nbr of Employees 34
Free-Float 89,9%
Chart NEPHROS, INC.
Duration : Period :
Nephros, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,46 $
Average target price 5,13 $
Spread / Average Target 251%
EPS Revisions
Managers and Directors
Andrew Astor President, Chief Executive Officer, CFO & Director
Michael Milman Vice President-Research & Development
Oliver Spandow Independent Director
Alisa Lask Independent Director
Thomas Gwydir Independent Director
Sector and Competitors